{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-104145","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2026-09-01T12:30:46+00:00","discovered_at":"2026-09-01T12:35:00.331119+00:00","generated_at":"2026-09-01T12:35:09.907762+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alumis LUMUS Phase 2b misses primary endpoint in SLE; IFNGS-high subgroup shows robust responses","bullets":["LUMUS Phase 2b (n=408) did not meet primary endpoint BICLA at Week 48 in overall SLE population.","Prespecified IFNGS-high subgroup showed robust responses on BICLA, CLASI-50, SRI-4, and LLDAS.","Dose-dependent target engagement with maximal suppression at 40mg BID; no new safety signals observed.","Alumis plans regulatory engagement to discuss Phase 3 development for envudeucitinib in SLE.","NDA submission for envudeucitinib in moderate-to-severe plaque psoriasis remains on track for 4Q 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-104145","json":"https://secwatch.observer/filing/0001104659-26-104145.json","markdown":"https://secwatch.observer/filing/0001104659-26-104145.md","text":"https://secwatch.observer/filing/0001104659-26-104145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/0001104659-26-104145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-01T12:35:09.907762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}